A Phase 1b Expansion Study of TAS-102 With Oxaliplatin For Refractory Metastatic Colorectal Cancer

BACKGROUND: TAS-102, a novel antimetabolite, is approved for treatment refractory metastatic colorectal cancer (CRC). We aimed to determine whether the addition of TAS-102 to oxaliplatin (TAS-OX) was safe and effective in metastatic CRC previously treated with oxaliplatin. METHODS: This investigator...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer
Autori principali: Cecchini, Michael, Kortmansky, Jeremy S., Cui, Can, Wei, Wei, Thumar, Jaykumar Ranchobdhai, Uboha, Nataliya V., Hafez, Navid, Lacy, Jill, Fischbach, Neal A., Sabbath, Kert D., Gomez, Christina M., Sporn, Jonathan Reed, Stein, Stacey, Hochster, Howard S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085021/
https://ncbi.nlm.nih.gov/pubmed/33351187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33379
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi